Capital
MoonLake revives FDA push; biotech trio to debut in Hong Kong
MoonLake Immunotherapeutics; Sonelokimab; Hidradenitis Suppurativa; FDA Type B meeting; Biologics License Application; BLA H2 2026; VELA-1 trial; VELA-2 trial; MIRA trial; HS drug approval pathway; investor day February 23 2026; Hong Kong biotech IPOs; Hong Kong listing; Asia biotech capital markets
Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets
Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson
Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets
Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson
Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets
Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson
Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets
Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson
Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant; IMVT; common stock offering; $550 million financing; equity financing; underwritten offering; IMVT-1402; Roivant Sciences; Leerink Partners; biotech capital raise
Expert Insights to Navigate Your CGT Challenges: Recent Updates and Strategic Guidance for 2025
capital gains tax; CGT challenges; 2025 tax rates; long-term capital gains; tax planning; tax minimization strategies; Net Investment Income Tax; private equity tax changes
Langers Team Launch $77.5M Fund to Invest at Intersection of Technology and Biology
T.Rx Capital; Robert Langer; Michael Langer; intersection of technology and biology; biotech investments; venture capital; Fund I
Amgen to Invest Over $600M in New Innovation Centre at California Headquarters
Amgen; innovation centre; science and innovation hub; Thousand Oaks; California; biotechnology; construction; automation; digital tools; therapeutic development; tax incentives; capital investment
Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders
Bluebird; private equity buyout; shareholders; upfront cash; Carlyle; SK Capital; contingent value right; CVR; buyout terms; merger